Please assess the completion status of the following clinical trial:

Trial Title: Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~An eligible subject must fulfill all of the following inclusion criteria:~* Signed informed consent (IC) obtained before any study specific procedure. Patients must be able to understand and willing to sign the written IC.~* Pathologically confirmed gastrointestinal stromal tumours.~* All patients had received imatinib or sunitinib.~* Pathological confirmed c-kit exon 17 mutation.~* At least one measurable lesion in a non-irradiated area or allowed to be tracked whether there are circumstances recurrence by computed tomography (CT) or magnetic resonance imaging (MRI).~* Aged \> 20 years old.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~* Life expectancy greater than 12 weeks.~* Adequate bone marrow function: 1) Absolutely neutrophil count \>= 1.5 x10\^9/L or white blood cell count (WBC) \>= 4x10\^9/L; 2) Hemoglobin \>= 9 g/dL; 3) Platelet count \>= 100x10\^9/L.~* Adequate liver function: 1) Total bilirubin \<= 1.5x the upper limit of normal (ULN); 2) Alanine Aminotransferase (ALT) \& Aspartate Aminotransferase (AST) \<= 2.5x ULN if without liver metastasis or \<= 5x ULN if with hepatic metastasis; 3) Alkaline phosphatase \<= 2.5x ULN if without liver metastasis or \<= 5x ULN if with hepatic metastasis or bone metastasis; 4) Bilirubin \< 2x ULN.~* Adequate renal function: creatinine \<1.5x ULN.~* Patients must be accessible for treatment and follow-up in the participating centers.~Exclusion Criteria:~Subject will not meet any of the following exclusion criteria:~* Major surgery within four weeks prior to entering the study.~* Patients with central nervous system (CNS) metastasis, including clinical suspicion.~* Patients who are under active or uncontrolled infections.~* Patients who with unstable angina (angina symptoms at rest, new-onset angina (begun within the last 3 months) or myocardial infarction history 6 months before entry.~* Cardiac arrhythmia requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).~* Congestive heart failure New York Heart Association (NYHA) class 2.~* Uncontrolled hypertension (systolic blood pressure \[BP\] \> 150 mmHg or diastolic pressure \> 90 mmHg despite optimal medical management.~* Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication.~* Patients who are pregnant or with breast feeding.~* Other concomitant or previously malignancy within 5 years except for in situ cervix cancer or squamous cell carcinoma of the skin treated by surgery only.~* Mental status is not fit for clinical trial.~* Cannot take study medication orally.~* Fertile men and women unless using a reliable and appropriate contraceptive method.~* Patients with evidence or history of any bleeding diathesis, irrespective of severity.~* Any hemorrhage or bleeding event \>= Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 within 4 weeks prior to the start of study medication.~* Non-healing wound, ulcer, or bone fracture.~* Renal failure requiring hemo-or peritoneal dialysis.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- regorafenib (Type: EXPERIMENTAL): regorafenib 160 mg daily, 3 weeks on/1 week off

Based on this trial design, predict the completion outcome and termination type (if applicable).